Transaction DateRecipientSharesTypePriceValue
22nd December 2020Management Inc. Opaleye496,277Open or private purchase$8.06$3,999,992.62
22nd December 2020Management Inc. Opaleye657Open or private purchase$5.19$3,412.98
22nd December 2020Management Inc. Opaleye15,900Open or private purchase$5.19$82,597.32
21st December 2020Management Inc. Opaleye51,400Open or private purchase$5.24$269,305.16
21st December 2020Management Inc. Opaleye2,059Open or private purchase$5.24$10,787.92
18th December 2020Management Inc. Opaleye35,000Open or private purchase$5.31$185,941.00
18th December 2020Management Inc. Opaleye1,400Open or private purchase$5.31$7,437.64
2nd November 2020Charles J Casamento3,000Open or private sale$30.29$90,863.70
21st October 2020Management Inc. Opaleye3,000Open or private purchase$4.40$13,190.70
21st October 2020Management Inc. Opaleye5,656Open or private purchase$4.40$24,868.87
Eton Pharmaceuticals
Eton Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Eton Pharmaceuticals, Inc. engages in the development and commercialization of prescription drug products. Its portfolio consists of injectable, oral liquid, ophthalmic products pipelines.

Ticker: ETON
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1710340
Employees: 17
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.
Red Flags
Red Flag analysis based on Klaus Henselmann / Elisabeth Scherr paper
Fundamentals
Red Flag analysis based on Klaus Henselmann / Elisabeth Scherr paper
News
Generic placeholder
Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI® SPRINKLE

14th January 2021

Generic placeholder
Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Topiramate Oral Solution

17th December 2020

Generic placeholder
Eton Pharmaceuticals Announces Availability of Orphan Drug ALKINDI® SPRINKLE (hydrocortisone) in the United States

24th November 2020

Generic placeholder
Eton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q3 2020 Results - Earnings Call Transcript

13th November 2020

Generic placeholder
Eton Pharmaceuticals Announces Third Quarter 2020 Financial Results

12th November 2020

Generic placeholder
DXP Enterprises Reports Third Quarter 2020 Results

6th November 2020